<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-99464</identifier>
<setSpec>0004-2927</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">4, 5-DIHYDRO-1H-PYRAZOLE as nNOS selective inhibitors: Synthesis and structure-activity relationship</dc:title>
<dc:description xml:lang="en">INTRODUCTION: Nitric Oxide Synthase (NOS) is the enzyme which catalyses the biosynthesis of Nitric Oxide (NO)from L-arginine 1. Four NOS isoforms have been described: 2 nNOS, iNOS, eNOS and mtNOS. NO is a biological messenger involved in several physiologic processes. 3 However, an over production of NO by nNOS produces neurotoxicity which has been associated with various neurological disorders 4.Therefore, it is necessary to found nNOS inhibitors to fight pathologies such as Alzheimer&#146;s disease, Parkinson, amyotrophic lateral sclerosis and Huntington&#146;s disease. In previous papers, our research group have described the synthesis of a series of kynurenine 5 1 and kynurenamine 6 2 derivatives as neuroprotective agents which are not active versus kynurenine-3-hydroxylase (KYN3OH). This fact demonstrates that their neuroprotective activity is only due to then NOS inhibition. 2 3                                            OBJECTIVE: Basing on these precedents, we have developed and evaluated in vivo, versus nNOS and iNOS, a series of 4,5-dihydro-1H-pyrazole derivatives with general structure 3 in order to find new selective compounds.                     METHODOLOGY: Taking kynurenine and kynurenamine derivatives as reference, we have synthesized rigid analogous with a ring of 4,5-dihydro-1H-pyrazole . Besides the conformacional restriction, other modification shave been carried out, as the introduction of different substituents in the aromatic ring and the modification of the acyl group in the pyrazoline ring .                                        CONCLUSION /DISCUSION: All compounds inhibit nNOS. In most of cases, the inhibition of iNOS is negligible. Thus, they can be considered selective. On the other hand, there is no KYN3OH inhibition. Consequently, the neuroprotective potential of these derivatives is due only to the inhibition of nNOS(AU)</dc:description>
<dc:creator>Carrión, M. D</dc:creator>
<dc:creator>Espinosa, A</dc:creator>
<dc:creator>Chayah, M</dc:creator>
<dc:creator>Gallo, M. A</dc:creator>
<dc:creator>Entrena, A</dc:creator>
<dc:creator>Acuña-Castroviejo, D</dc:creator>
<dc:creator>Camacho, M. E</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">CONCLUSIÓN /DISCUSIÓN: Todos los compuestos ensayados inhiben nNOS. La inhibición de iNOS es ínfima en la mayoría de los casos, por lo que se pueden considerar selectivos, y no hay inhibición de KYN3OH. Por consiguiente, el potencial neuroprotector de estos derivados se debe únicamente a la inhibición de nNOS(AU)</dc:description>
<dc:source>Ars pharm;51(supl.3): 77-83, jul. 2010. ilus, tab</dc:source>
<dc:identifier>ibc-99464</dc:identifier>
<dc:title xml:lang="es">Derivados de 4, 5-DIHIDRO-1H-PIRAZOL como inhibidores selectivos de nNOS: Síntesis y relaciones estructura-actividad</dc:title>
<dc:subject>^d704^s22057</dc:subject>
<dc:subject>^d32663^s22007</dc:subject>
<dc:subject>^d32116^s22073</dc:subject>
<dc:subject>^d545^s22057</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d30920^s22057</dc:subject>
<dc:subject>^d10489^s22057</dc:subject>
<dc:subject>^d32663^s22073</dc:subject>
<dc:type>article</dc:type>
<dc:date>201007</dc:date>
</metadata>
</record>
</ibecs-document>
